BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

Mingxing Wang; Wanjun Li; Xuemei Xing; Dan Zhang; Jie Lei; Guoyin Li

doi:10.18632/oncotarget.20715

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

Mingxing Wang, Wanjun Li, Xuemei Xing, Dan Zhang, Jie Lei _ and Guoyin Li

PDF | HTML | How to cite

Oncotarget. 2017; 8:80869-80877. https://doi.org/10.18632/oncotarget.20715

Metrics: PDF 1257 views | HTML 2240 views | ?

Abstract

Mingxing Wang1,*, Wanjun Li2,*, Xuemei Xing3,*, Dan Zhang4, Jie Lei1 and Guoyin Li2,5

1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi’an, Shaanxi, China

2Department of Pathology, Hanzhong 3201 Hospital Affiliated to Xi’anJiaotong University, Xi’an, Shaanxi, China

3Department of Clinical Laboratory, Hanzhong 3201 Hospital Affiliated to Xi’anJiaotong University, Xi’an, Shaanxi, China

4Department of Oncology, Hanzhong 3201 Hospital Affiliated to Xi’anJiaotong University, Xi’an, Shaanxi, China

5Department of Biochemistry and Molecular Biology, The Fourth Military Medical University, Xi’an, Shaanxi, China

*These authors are co-first authors

Correspondence to:

Jie Lei, email: [email protected]

Guoyin Li, email: [email protected]

Keywords: NSCLC, BRCA1 and STMN, chemotherapy, prognosis

Received: April 03, 2017 Accepted: August 08, 2017 Published: September 08, 2017

ABSTRACT

Objective: In this study, we aimed to investigate the predictive effect of BRCA1, STMN1, MAPT and TUBB3 on the prognosis of patients with non-small cell lung cancer (NSCLC).

Methods: Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protein and mRNA levels of BRCA1, STMN1, MAPT and TUBB3 were determined. Survival time of the patients with NSCLC was also calculated.

Results: High expression of BRCA1 or low expression of STMN1 was associated with a better prognosis in NSCLC patients (p<0.01). In contrast, the expression of MAPT and TUBB3 were not closely related with the prognosis of NSCLC patients(p>0.05). Furthermore, patients with high expression of BRCA1 and low expression of STMN1 have lived longer (p<0.01).

Conclusion: BRCA1 and STMN1 were independently predictors for prognosis of NSCLCs which received cisplatin-based adjuvant chemotherapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20715

Publication Alerts

Research Papers:

BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

Abstract